GlassScriptPhysician profile
Shannon Greenquist
NPI 1174062368
$8,879.52
in general payments reported to CMS, 2019-2025
32 companies · $2,134 in 2025
The $2,134 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,205 · 2022: $2,297 · 2023: $1,760 · 2024: $1,484 · 2025: $2,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,377.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,043.17 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Novartis Pharmaceuticals Corporation | $888.66 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.26 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $623.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $618.65 | 2021-2025 | |
| Amgen INC. | $569.10 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $539.60 | 2021-2025 | Verquvo, Capvaxive, Winrevair |
| Pfizer INC. | $529.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $475.84 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $397.03 | 2021-2024 | Lifevest |
| Preventric Diagnostics, INC. | $366.08 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $282.44 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Abbott Laboratories | $280.93 | 2021-2025 | Cardiomems, Mitraclip |
| Alnylam Pharmaceuticals INC. | $242.41 | 2021-2025 | Amvuttra, Onpattro |
| Sanofi-Aventis U.S. LLC | $204.34 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $188.99 | 2022 | |
| Bridgebio Pharma, INC. | $148.69 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $136.06 | 2022-2024 | Eliquis |
| Vifor Pharma, INC. | $109.96 | 2022-2023 | Veltassa |
| Scpharmaceuticals INC. | $107.81 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $86.78 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $82.58 | 2022-2025 | Evkeeza, Praluent |
| Lexicon Pharmaceuticals, INC. | $59.17 | 2023-2024 | Inpefa |
| Surmodics, INC. | $42.19 | 2023 | Pounce Venous Thrombectomy System, Sublime Radial Access 018 Rx Pta Dilatation Catheter, Sublime 014 Rx Pta Balloon Dilatation Catheter |
| Esperion Therapeutics, INC. | $41.72 | 2021 | |
| Amarin Pharma, INC. | $36.00 | 2021 | |
| Chiesi USA, INC. | $28.04 | 2021-2024 | Cleviprex, Kengreal |
| Ionis Pharmaceuticals, INC. | $25.56 | 2025 | Tryngolza |
| Kiniksa Pharmaceuticals, LTD. | $24.19 | 2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $23.81 | 2023 | Optimizer |
| Inogen, INC. | $19.54 | 2025 | |
| Janssen Biotech, INC. | $7.16 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Greenquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.